Clinical Trial Update: Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm [Phase 2]

View source ↗

Summary

Phase 2 trial investigating postoperative pembrolizumab for patients with solid predominant or micropapillary lung adenocarcinoma, stage I, tumor size >4 cm.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Lung Adenocarcinoma, Stage I | Phase 2 | Status: UNKNOWN